TSUMURA, DAINIPPON PHARMACEUTICAL TO CEASE DEVELOPMENT OF LERCANIDIPINE HYDROCHLORIDE

Tsumura and Dainippon Pharmaceutical have decided to return their right to develop and sell lercanidipine hydrochloride, a hypertension drug candidate, in Japan to Recordati, an Italian pharmaceutical. The two Japanese companies have jointly worked on the development of lercanidipine hydrochloride. However, their latest study indicated that the agent will not be a competitive product in Japan. Consequently, the two companies have announced the decision.

Investor's Business Daily (http://www.investors.com/breakingnews.asp?journalid=30655234&brk=1)